The technology provides a platform of diagnostic tests used by physicians and researchers to monitor the success of anti-HIV treatment by determining drug resistance and disease strength of the virus. The technology can also be used for academic research to better understand this virus and to develop better vaccines.
In June 2008, Diagnostic Hybrids and Case Western Reserve were recipients of a $5 million grant from the Ohio third frontier biomedical research and commercialization program to accelerate the commercial development of a suite of diagnostic products using the yeast vector technology, including products and services related to HIV, hepatitis and influenza.
David Scholl, president and CEO of Diagnostic Hybrids, said: This licensing agreement, our most recent success in combining our effort to win support from the prestigious third frontier program, and the unusually high skill, collaborative talent, and overall commercial leadership on this project will prove pivotal to our translating the science into commercial opportunity for Diagnostic Hybrids and jobs in Ohio.